12-year positive survival data for BSD's hyperthermia therapy:
This article was originally published in Clinica
Executive Summary
A 12-year follow-up study has shown positive survival rates for BSD Medical's precision-focused hyperthermia therapy device, BSD-2000, when used as an enhancement to radiotherapy. The 358-patient study assessed patients with locally-advanced pelvic tumours, and many had extremely poor prognoses. The follow-up found that patients who received radiation plus hyperthermia therapy had a survival rate of 37%, compared with 20% for those receiving radiation alone. Furthermore, the margin of increased survival rate of patients was similar at 12 years (an 85% increase) as at 3 years (an 89% increase). One of the primary concerns about new therapies is their durability, said Salt Lake City, Utah-based BSD. The findings were presented at the European Society for Hyperthermic Oncology, in Prague, Czech Republic, in June.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.